 | Up a level |
2018
Mato, Anthony R., Yazdy, Maryam Sarraf, Hill, Brian T., Shadman, Mazyar, Tuncer, Hande, Winter, Allison M., Kennard, Kaitlin, Allan, John N., Ujjani, Chaitra S., Brander, Danielle M., Nabhan, Chadi, Barr, Paul 
ORCID: 0000-0002-9733-401X, Brown, Jennifer R., Fox, Christopher P., Rhodes, Joanna, Schuh, Anna, Eyre, Toby A., Lamanna, Nicole, Jain, Nitin, Wierda, William G., Skarbnik, Alan P., Roeker, Lindsey E., Bannerji, Rajat, Evens, Andrew M., Lansigan, Frederick, Samp, Jennifer C., Nielsen, Jacqueline, Pauff, James M., Kipps, Thomas J., Schuster, Stephen J., Follows, George A., Cheson, Bruce and Eichhorst, Barbara
(2018).
Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study.
Blood, 132.
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020
2017
Robak, Tadeusz, Hellmann, Andrzej, Kloczko, Janusz, Loscertales, Javier, Lech-Maranda, Ewa ORCID: 0000-0001-9592-0851, Pagel, John M., Mato, Anthony, Byrd, John C., Awan, Farrukh T., Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Eisenfeld, Amy J., Stromatt, Scott C. and Jaeger, Ulrich
(2017).
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Br. J. Haematol., 176 (4).
S. 618 - 629.
HOBOKEN:
WILEY.
ISSN 1365-2141
2014
Robak, Tadeusz, Hellman, Andrzej, Loscertales, Javier, Lech-Maranda, Ewa ORCID: 0000-0001-9592-0851, Pagel, John M., Mato, Anthony R., Byrd, John C., Awan, Farrukh ORCID: 0000-0003-1813-9812, Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Stromatt, Scott and Kloczko, Janusz
(2014).
Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR (TM) Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results.
Blood, 124 (21).
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020